SUPPORTING INFORMATION

Table S1. Human cell lines used in these studies and their respective biomarker status and subtype. ER (estrogen receptor), PR (progesterone receptor), HER2 (ErbB2).

| Cell Line | Source | Tumor Type | Subtype | ER | PR | HER2 |
|------------|-------------------------|---------------------------------|-------------------------------|----|----|------|
| BT-474 | Primary breast | Ductal carcinoma | Luminal B | + | + | + |
| DU4475 | Mammary gland | Epithelial cell | TNBC, IM subtype | - | - | - |
| HeLa | Cervix | Adenocarcinoma | N/A | | | |
| MCF-7 | Pleural effusion | Invasive ductal carcinoma | Luminal A | + | + | - |
| MCF10A | Primary breast | Epithelial cell, nontumorigenic | Basal | - | - | - |
| MDA-MB-231 | Pleural effusion | Adenocarcinoma | Claudin-low or basal- like | - | - | - |
| LiSa-2 | Pleomorphic liposarcoma | Liposarcoma | N/A | | + | |
| SKBR3 | Pleural effusion | Adenocarcinoma | Luminal | - | - | + |
| T47-D | Pleural effusion | Invasive ductal carcinoma | Luminal A | + | + | - |

Table S2. Gene primer sequences used for detection in qRT-PCR analysis.

| Gene (GenBank) | Product Designation | | |
|----------------|-----------------------|--|--|
| ACACA | Hs01046047_m1 ACACA | | |
| ACLY | Hs00982738_m1 ACLY | | |
| ACSS2 | Hs01122829_m1 ACSS2 | | |
| Сус | 4310883E | | |
| CD36 | Hs00354519_m1 CD36 | | |
| DGAT1 | Hs01020362 g1 | | |
| FASN | Hs01005622_m1 FASN | | |
| GPIHBP1 | Hs01564843_m1 GPIHBP1 | | |
| HMGCR | Hs00168352_m1 HMGCR | | |
| LDLR | Hs 01092524_m1 LDLR | | |
| LMF1 | Hs01071616_m1 LMF1 | | |
| LPL | Hs00173425_m1 LPL | | |
| PLIN2 | Hs00605340_m1 PLIN2 | | |
| SCD | Hs01682761_m1 SCD | | |



Figure S1. Cell line expression of select genes involved in FFA and VLDL uptake. Basal gene expression of (A) LPL, (B) VLDLR, and (C) CD36 was assessed using qRT-PCR (note different scales). Relative expression values are displayed as $2^{-\Delta CT}$, with Cq of the target normalized to that of cyclophilin. Data are mean +/- SEM of > 3 experiments.



Figure S2. The HSPG Motif (GlcNS6S-IdoA2S)₃, a binding site for LPL, is expressed on the surface of cancer cells. (A) The abundance of HS^{NS4F5} on the surface of cell lines was assessed by flow cytometry. Relative MFI is the median fluorescence of cells stained with the NS4F5^{IgG}-Dylight 650 antibody normalized to the NS4F5^{null}-Dylight 650 control. (B) Confocal microscopy of MDA-MB-231 cells stained with Hoechst 33342 nuclear stain (blue) and DyLight 650 NS4F5^{IgG} or NS4F5^{null}antibody (green) for 30 min at 4°C localizes HS^{NS4F5} to the cell surface. (C) shRNA knockdown of heparan sulfate 6-O-sulfotransferase 1 (HS6ST1) reduces HS^{NS4F5} on the surface of MDA-MB-231 BC cells, assessed by flow cytometry. Relative MFI represents the median fluorescence of cells stained with the NS4F5^{IgG}-Dylight 650 antibody normalized to those stained with the isotype control, NS4F5^{null}-Dylight 650. ***p < 0.001, two-tailed unpaired t-test with Welch's correction.



Figure S3. Both lipid and protein component of VLDL particles bind to- and are internalized by MDA-MB-231 and MCF-7 BC cells. Confocal microscopy of BC cells incubated with Dil (lipid-) and DyLight 650 (protein-) co-labeled VLDLs. Three channels are shown: Hoechst 33342 nuclear stain (blue), DiI-VLDL (red), DyLight650-VLDL (green). Orange spots (in merged channel) are where DiI and DyLight650 fluorescence coincide.



Figure S4. Cell surface DiI-VLDL binding is specific. Competition with excess unlabeled VLDL inhibits DiI-VLDL binding at 4°C. MDA-MB-231 cells were treated with DiI-VLDL (5 μ g/mL) with or without unlabeled VLDL (5 or 10 μ g/mL). DiI-VLDL (red); DAPI nuclear stain (blue).



Figure S5. Characterization of MDA-MB-231 LPL shRNA cell lines. (A) qRT-PCR products run on agarose gels. Parental and scrambled shRNA cell lines are compared to LPL shRNA A (complete knockdown of LPL) and LPL shRNA D (partial knockdown). (B) qRT-PCR of MDA-MB-231 manipulated cell lines normalized to the pooled control. LPL shRNA A cells exhibit significant upregulation of mRNAs involved in *de novo* lipid synthesis (ACACA, ACLY, FASN), cholesterol synthesis (HMGCR), and FA uptake (CD36, LMF1, VLDLR). MDA-MB-231 LPL shRNA D (partial LPL knockdown) cells display a significant upregulation of VLDLR expression alone. *P < 0.05, **p < 0.01, ***p < 0.001. Error is SEM. (C) Comparison of DiI-VLDL uptake in Scr and LPL shRNA cells with and without treatment (heparin 500 µg/mL; dynasore 80 µM), measured by flow cytometry. MDA-MB-231 LPL shRNA A cells, ***p < 0.001. All three cell lines showed significant reductions in DiI-VLDL uptake following treatment with heparin or dynasore, ***p < 0.001.



Figure S6. Trends in the expression of FA metabolic genes in BC cell lines cultured in lipoproteindepleted serum media for 96 h. Gene expression was measured using qRT-PCR. Results were calculated using the $2^{-\Delta\Delta CT}$ method first normalized to cyclophilin, and then made relative to that of the matched FBS media control. Data are from > 3 experiments; error is SEM. Statistical significance determined using twotailed unpaired t-tests: *P < 0.05, **p < 0.01, ***p < 0.001.